COMPARISON OF PREDICTIVE ACCURACY FOR PATHOLOGICALLY ORGAN CONFINED CLINICAL STAGE T1c PROSTATE CANCER USING HUMAN GLANDULAR KALLIKREIN 2 AND PROSTATE SPECIFIC ANTIGEN COMBINED WITH CLINICAL STAGE AND GLEASON GRADE
2005; Lippincott Williams & Wilkins; Volume: 173; Issue: 3 Linguagem: Inglês
10.1097/01.ju.0000152618.38747.dd
ISSN1527-3792
AutoresAlexander Haese, Ville Väisänen, Hans Lilja, Michael W. Kattan, Harry G. Rittenhouse, Kim Pettersson, Daniel W. Chan, Hartwig Huland, Lori J. Sokoll, Alan W. Partin,
Tópico(s)Statistical Methods in Clinical Trials
ResumoNo AccessJournal of UrologyAdult Urology: Oncology: Prostate/Testis/Penis/Urethra1 Mar 2005COMPARISON OF PREDICTIVE ACCURACY FOR PATHOLOGICALLY ORGAN CONFINED CLINICAL STAGE T1c PROSTATE CANCER USING HUMAN GLANDULAR KALLIKREIN 2 AND PROSTATE SPECIFIC ANTIGEN COMBINED WITH CLINICAL STAGE AND GLEASON GRADE ALEXANDER HAESE, VILLE VAISANEN, HANS LILJA, MICHAEL W. KATTAN, HARRY G. RITTENHOUSE, KIM PETTERSSON, DANIEL W. CHAN, HARTWIG HULAND, LORI J. SOKOLL, and ALAN W. PARTIN ALEXANDER HAESEALEXANDER HAESE , VILLE VAISANENVILLE VAISANEN , HANS LILJAHANS LILJA , MICHAEL W. KATTANMICHAEL W. KATTAN , HARRY G. RITTENHOUSEHARRY G. RITTENHOUSE , KIM PETTERSSONKIM PETTERSSON , DANIEL W. CHANDANIEL W. CHAN , HARTWIG HULANDHARTWIG HULAND , LORI J. SOKOLLLORI J. SOKOLL , and ALAN W. PARTINALAN W. PARTIN View All Author Informationhttps://doi.org/10.1097/01.ju.0000152618.38747.ddAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Previously human glandular kallikrein 2 (hK2) has been implicated to predict pathologically organ confined prostate cancer (PCa) in patients with stage T2 disease. Now we evaluated the usefulness of hK2, as measured by 2 entirely different immunoassay designs, to enhance the discrimination of pathologically organ from nonorgan confined clinical stage T1c PCa. Materials and Methods: A consecutive series of pretreatment serum from 148 men with clinical stage T1c PCa was used in 2 equally sensitive and specific methods to measure total hK2 with independent reagents and entirely different assay designs. Total prostate specific antigen (tPSA) and free PSA (fPSA) were measured and percent fPSA was calculated. We determined the algorithm, hK2*tPSA/fPSA, from data generated by each hK2 assay, calculated means, medians and ranges for each analyte and algorithm, and calculated the significance of differences on univariate analysis. Using pretreatment PSA, clinical stage and biopsy Gleason grade we then developed a multivariate logistic regression base model to predict organ confined cancer and we compared predictions of the base model supplemented by the different hK2 measurements. Results: hK2 and hK2 based algorithms obtained by each hK2 assay were significantly different for pT2a/b vs pT3a or greater PCa (p = 0.034 to 0.0001) compared to tPSA (p = 0.06), fPSA (p = 0.90) or percent fPSA (p = 0.059). However, AUC (0.67 to 0.70) calculated by ROC analysis of the 4 models containing hK2 derived information was not significantly larger than that of the base model (AUC = 0.64, p = 0.52). Conclusions: The current data confirm that hK2 alone or hK2*tPSA/fPSA measured by 2 immunoassays is significantly lower in men with pT2a/b vs pT3a or greater PCa compared to tPSA, fPSA or percent fPSA on univariate analysis of a validation set of clinical stage T1c prostate cancer treated at an American center of excellence for prostate cancer surgery. However, the incorporation of preoperative hK2 into multiparameter predictive models for pT2 cancers did not increase predictive accuracy in this cohort of men. References 1 : The National Cancer Data Base report on longitudinal observations on prostate cancer. Cancer1996; 77: 2162. Google Scholar 2 : Stage migration in clinically localized prostate cancer. Eur Urol2000; 38: 74. Google Scholar 3 : Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol1994; 151: 1283. Abstract, Google Scholar 4 : Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol1990; 143: 747. Link, Google Scholar 5 : Primary structure of a human glandular kallikrein gene. DNA1987; 6: 429. Google Scholar 6 : Tissue-specific and hormonal regulation of human prostate-specific glandular kallikrein. Biochemistry1992; 31: 818. Google Scholar 7 : Measurement of prostate-specific antigen and human glandular kallikrein 2 in different body fluids. J Androl1999; 20: 348. Google Scholar 8 : Sensitive and specific immunodetection of human glandular kallikrein 2 in serum. Clin Chem2000; 46: 198. Google Scholar 9 : Immunofluorometric assay for sensitive and specific measurement of human prostatic glandular kallikrein (hK2) in serum. Clin Chem1996; 42: 1034. Google Scholar 10 : Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. Biochem Biophys Res Commun1997; 238: 549. Google Scholar 11 : Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. Urology1997; 49: 857. Google Scholar 12 : Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases. Urology1999; 53: 939. Google Scholar 13 : Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus nonorgan confined growth of prostate cancer. J Urol2000; 163: 1491. Link, Google Scholar 14 : Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml. Prostate2001; 49: 101. Google Scholar 15 : Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen. Urology2000; 55: 481. Google Scholar 16 : Development of a dual monoclonal antibody immunoassay for total human kallikrein 2. Clin Chem2001; 47: 1218. Google Scholar 17 : The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer. Prostate2003; 54: 181. Google Scholar 18 : Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millenium. Urology2001; 58: 843. Google Scholar 19 : A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst1998; 90: 766. Google Scholar 20 : A validated strategy for side specific prediction of organ confined prostate cancer: a tool to select for nerve sparing radical prostatectomy. J Urol2001; 165: 857. Link, Google Scholar From the Departments of Urology (AH, DWC, LJS, AWP) and Pathology (DWC, LJS, AWP), The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, Maryland, Hybritech-Beckman Coulter, Inc. (HGR), San Diego, California, Department of Biotechnology, University of Turku (VV, KP), Turku, Finland, Department of Clinical Laboratories, Urology and Medicine, Memorial Sloan-Kettering Cancer Center (HL, MWK), New York, New York, Division of Clinical Chemistry, Department of Laboratory Medicine, Lund University, University Hospital (UMAS) (HL), Malmö, Sweden, and Department of Urology, University Eppendorf (HH), Hamburg, Germany© 2005 by American Urological Association, Inc.FiguresReferencesRelatedDetails Volume 173Issue 3March 2005Page: 752-756 Advertisement Copyright & Permissions© 2005 by American Urological Association, Inc.Keywordsimmunoassayprostate-specific antigenprostatic neoplasmsprostatetissue kallikreinsMetricsAuthor Information ALEXANDER HAESE More articles by this author VILLE VAISANEN More articles by this author HANS LILJA More articles by this author MICHAEL W. KATTAN More articles by this author HARRY G. RITTENHOUSE More articles by this author KIM PETTERSSON More articles by this author DANIEL W. CHAN More articles by this author HARTWIG HULAND More articles by this author LORI J. SOKOLL More articles by this author ALAN W. PARTIN More articles by this author Expand All Advertisement PDF downloadLoading ...
Referência(s)